Developing Pediatric Treatments for COVID-19

Virtual Workshop
May 28, 2020 – 10 am-12:30 pm

Moderators
Edward Connor, MD, MBE, Founder and Chairman, I-ACT for Children
Susan McCune, MD, Director, Office of Pediatric Therapeutics, US Food and Drug Administration

Agenda

10-10:10 am
Welcome
Laura Gordon, Chief Executive Officer, I-ACT for Children

Introduction: Focusing on COVID-19 Research and Children
Edward Connor, MD, MBE

I. Background

10:10-10:25 am
COVID-19 in Pediatric Populations
- Collin Hovinga, PharmD, SVP, Clinical & Scientific Development, I-ACT for Children
- Seth Kuranz, Principal Epidemiologist, TriNetX

10:25-10:35 am
Diagnosis, Clinical Presentation and Outcomes of Children with COVID-19
Roberta DeBiasi, MD, MS, Chief, Infectious Diseases, Children’s National Medical Center

II. Approach to Pediatric Therapeutics Development in COVID-19

10:35-10:55 am
Current State of Drug/Biologics Development
- Gary Noel, MD, Chief Medical Officer, I-ACT for Children
- Lynne Yao, MD, Director, Division of Pediatric and Maternal Health, Urologic and Reproductive Medicine; Center for Drug Evaluation and Research, US Food and Drug Administration

10:55-11:05 am
Innovative Methods for Conducting Pediatric Clinical Trials
Lily Mulugeta, PharmD, Associate Director for Science, Division of Pediatric and Maternal Health, US Food and Drug Administration
11:05-11:25 am
Antiviral Drug Development: Drugs and Biologics
- Cheryl Pikora, MD, PhD, Senior Medical Director, Global Clinical Research, Pediatric HIV and Pediatric Emerging Viruses Project Team Lead, Gilead Sciences, Inc
- Yodit Belew, MD, Senior Medical Officer, Division of Antiviral Products, Center for Drug Evaluation and Research, US Food and Drug Administration

11:25-11:50 am
Development of Immunomodulators
- Wallace Crandall, MD, MMM, Medical Fellow/Senior Medical Leader for Pediatric Immunology, Eli Lilly and Company
- Nikolay Nikolov, MD, Acting Director, Division of Rheumatology and Transplant Medicine, Office of Immunology and Inflammation, US Food and Drug Administration

11:50 am-Noon
Ethical considerations
John Lantos, MD, Professor of Pediatrics, University of Missouri–Kansas City School of Medicine, Director, Children's Mercy Bioethics Center, Children's Mercy Hospital

III. Panel Discussion and Q&A

Noon-12:25 pm
Moderator: Susan McCune, MD
Panelists (in addition to above presenters)
- Keira Sorrells, Founder & Executive Director, NICU Parent Network
- John Bradley, MD, Medical Director, Division of Infectious Diseases, Rady Children’s Hospital-San Diego
- Octavio Ramilo, MD, Henry G. Cramblett Chair in Infectious Diseases and Professor of Pediatrics at the Ohio State University College of Medicine; Chief of Infectious Diseases at Nationwide Children’s Hospital
- Aaron C Pawlik, PhD, Chief, Obstetric and Pediatric Pharmacology and Therapeutics Branch; Division of Extramural Research; Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH

12:25-12:30 pm
Closing Remarks
Ed Connor, MD, MBE
Susan McCune, MD